Skip to main content

Advertisement

Table 4 Prognostic factors for distant disease-free survival: univariate analysis

From: Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

  N 5-Year DDFS (%) (95 % CI) HR (95 % CI) p-valuea
Age
  < 35 30 82.6 [68.2–100] 1  
  ≥ 35 726 93.3 [91.2–95.4] 0.5 [0.2–1.3] 0.1223
SBR Grade
 1–2 462 96 [94–98] 1  
 3 285 87.4 [82.9–92.1] 2.8 [1.6–4.9] 0.0002
Pathological tumor size
 pT1 391 93.6 [90.9–96.5] 1  
 pT2 320 92.3 [88.9–95.7] 1.2 [0.7–2]  
 pT3-T4 36 88.2 [78–99.8] 1.6 [0.6–4.7] 0.6395
PVI
 No 558 94.2 [92–96.5] 1  
 Yes 178 88.8 [83.5–94.5] 2.2 [1.3–4] 0.0042
Hormone receptors
 Negative 208 88 [83–93.4] 1  
 Positive 526 94.7 [92.5–96.9] 0.6 [0.3–1] 0.049
HER2
 Negative 507 93.2 [90.5–95.9] 1  
 Positive 96 95.7 [91–100] 0.9 [0.3–2.2] 0.7719
IHC subtypes
 Luminal A 289 96.8 [94.5–99.2] 1  
 Luminal B/HER2-negative 82 85.5 [76.3–95.8] 4.6 [1.8–11.7]  
 Luminal B/HER2-positive 58 100 [100–100] 1.2 [0.2–5.5]  
 HER2 37 89 [77.6–100] 2.9 [0.8–11.1]  
 Triple-negative 127 89 [82.5–96] 3.3 [1.3–8.2] 0.0059
  1. HR hazard ratio, PVI peritumor vascular invasion
  2. aunadjusted log-rank test